Suppr超能文献

12 项银屑病关节炎疾病影响问卷的有效性和评分解读:在接受倍美克单抗治疗的银屑病关节炎患者的两项 3 期临床试验中汇总数据的分析。

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis.

机构信息

INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France

Rheumatology Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

出版信息

RMD Open. 2024 Jan 31;10(1):e003548. doi: 10.1136/rmdopen-2023-003548.

Abstract

OBJECTIVES

To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change thresholds and scores corresponding to different levels of symptom/impact severity.

METHODS

Data up to week 16 from 1252 patients with active PsA enrolled in two randomised controlled trials of bimekizumab (BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581)) were used to assess construct validity (correlations with other patient-reported outcomes), known-groups validity (based on Minimal Disease Activity index, Disease Activity Index for Psoriatic Arthritis and Psoriatic Arthritis Disease Activity Score), reliability (Cronbach's alpha and intraclass correlation coefficients (ICCs)) and responsiveness (sensitivity to change). Clinically meaningful within-patient improvement thresholds were estimated by anchor-based and distribution-based analyses, and symptom/impact severity thresholds were estimated by receiver operating characteristic curve analyses.

RESULTS

The mean (SD) PsAID-12 total score at baseline was 4.19 (1.94). PsAID-12 scores demonstrated good convergent validity and good known-groups validity. Internal consistency reliability (Cronbach's alpha 0.95) and test-retest reliability (ICC ≥ 0.70) were also good. Responsiveness was acceptable (correlations ≥0.30 for most scores). Improvement thresholds were estimated at 1.5-2 points for the PsAID-12 total score and 2 or 3 points for item scores. Thresholds for different levels of symptom/impact severity could be derived for most PsAID-12 items.

CONCLUSIONS

The PsAID-12 demonstrated robust psychometric properties in a large sample of patients with active PsA, supporting its use as a fit-for-purpose patient-reported outcome in this population. Furthermore, thresholds for score interpretation were derived.

摘要

目的

在患有银屑病关节炎(PsA)的患者中,调查 12 项银屑病关节炎疾病影响量表(PsAID-12)总分和各条目得分的心理测量性能,并估计评分变化阈值和与不同严重程度的症状/影响水平相对应的评分。

方法

使用来自两项倍美克单抗(BE OPTIMAL(NCT03895203)和 BE COMPLETE(NCT03896581))随机对照试验中 1252 例活动性 PsA 患者的截至第 16 周的数据,评估结构效度(与其他患者报告结局的相关性)、已知组有效性(基于最小疾病活动指数、银屑病关节炎疾病活动指数和银屑病关节炎疾病活动评分)、可靠性(克朗巴赫的 α 和组内相关系数(ICC))和反应性(对变化的敏感性)。通过基于锚定的和基于分布的分析估计患者内改善的临床有意义的阈值,通过接受者操作特征曲线分析估计症状/影响严重程度的阈值。

结果

基线时 PsAID-12 总分的平均值(标准差)为 4.19(1.94)。PsAID-12 评分表现出良好的收敛效度和良好的已知组有效性。内部一致性可靠性(克朗巴赫的α为 0.95)和重测可靠性(ICC≥0.70)也很好。反应性可接受(大多数评分的相关性≥0.30)。PsAID-12 总分的改善阈值估计为 1.5-2 分,条目得分的改善阈值估计为 2 分或 3 分。大多数 PsAID-12 条目的不同严重程度的症状/影响水平的阈值可以得出。

结论

在大量活动性 PsA 患者中,PsAID-12 表现出可靠的心理测量学特性,支持其在该人群中作为一种适合目的的患者报告结局使用。此外,还得出了评分解释的阈值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/121b/10831419/311f3db12044/rmdopen-2023-003548f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验